Almi­rall part­ners with eth­er­na; Dai­ichi's RNA deal with De­pixus; SQZ founder's start­up emerges from stealth

Plus, news on Antabio’s €25 mil­lion Se­ries B, Athi­ra’s Alzheimer’s da­ta, Con­nect’s asth­ma re­sults and Liq­uidia’s $25 mil­lion raise.

Almi­rall, eth­er­na’s new part­ner­ship: The com­pa­nies plan to de­vel­op new mR­NA ther­a­pies for se­vere skin dis­eases, in­clud­ing some skin can­cers. Almi­rall is pay­ing eth­er­na an undis­closed up­front pay­ment, plus up to €300 mil­lion ($324 mil­lion) in po­ten­tial mile­stones. — Jaimy Lee

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER